While some are satisfied with an index fund, active investors aim to find truly magnificent investments on the stock market. When you buy and hold the right company, the returns can make a huge difference to both you and your family. For example, the NeuroScientific Biopharmaceuticals Limited (ASX:NSB) share price is up a whopping 515% in the last 1 year, a handsome return in a single year. Also pleasing for shareholders was the 390% gain in the last three months. However, the stock hasn't done so well in the longer term, with the stock only up 4.3% in three years. Anyone who held for that rewarding ride would probably be keen to talk about it.

Since it's been a strong week for NeuroScientific Biopharmaceuticals shareholders, let's have a look at trend of the longer term fundamentals.

We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

In his essay The Superinvestors of Graham-and-Doddsville Warren Buffett described how share prices do not always rationally reflect the value of a business. By comparing earnings per share (EPS) and share price changes over time, we can get a feel for how investor attitudes to a company have morphed over time.

NeuroScientific Biopharmaceuticals was able to grow EPS by 54% in the last twelve months. The share price gain of 515% certainly outpaced the EPS growth. So it's fair to assume the market has a higher opinion of the business than it a year ago. The fairly generous P/E ratio of 67.25 also points to this optimism.

You can see below how EPS has changed over time (discover the exact values by clicking on the image).

This free interactive report on NeuroScientific Biopharmaceuticals' earnings, revenue and cash flow is a great place to start, if you want to investigate the stock further.

A Different Perspective

We're pleased to report that NeuroScientific Biopharmaceuticals shareholders have received a total shareholder return of 515% over one year. Since the one-year TSR is better than the five-year TSR (the latter coming in at 0.9% per year), it would seem that the stock's performance has improved in recent times. Given the share price momentum remains strong, it might be worth taking a closer look at the stock, lest you miss an opportunity. It's always interesting to track share price performance over the longer term. But to understand NeuroScientific Biopharmaceuticals better, we need to consider many other factors. For example, we've discovered 4 warning signs for NeuroScientific Biopharmaceuticals (2 are significant!) that you should be aware of before investing here.

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of companies we expect will grow earnings.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Australian exchanges.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.